GLP-1 agonists can improve liver enzyme levels and reduce liver fat content in individuals with T2DM and MASH [12,13]. Furthermore, an even newer dual GLP-1 and gastric inhibitory polypeptide (GIP) agonist medication called tirzepatide has shown superior efficacy compared to placebo in achieving the resolution of MASH without worsening liver fibrosis, according to recently published trial data [10]. This evidence concerns the gene GCG and Hepatic fibrosis.